

CASE STUDY: **Rapid Enrollment**

When a customer struggled to enroll patients in an HPV 16 study, it contacted Elligo Health Research for help. Elligo identified the target population within its women's health community and completed enrollment within three months — contributing 90% of all patients enrolled.

Elligo Finds Physicians and Patients



100+ healthcare partners



700+ physicians



Access to over
10,000 HPV patients



Largest women's health
community in the U.S.



Introduction

A leading HPV vaccine pharmaceutical company approached Elligo for help with a human papillomavirus (HPV) study. While there are more than 100 types of HPV, this customer was specifically studying HPV 16, which is a high-risk form that often doesn't have any noticeable symptoms but causes about half of all cervical cancers worldwide, according to the Centers for Disease Control and Prevention.

Up to 80% of trials fail to meet their enrollment objectives, and this study was no different. Months after enrollment had started, only one patient had been enrolled and the customer desperately needed an alternative strategy.

The Challenge

The study's protocol required patients who screened positive for HPV 16. However, the customer's previously selected sites did not have the ability to identify the type of HPV the patient was diagnosed with prior to screening. As a result, the study had an 84% screen failure rate, which is excessively high.

The customer turned to Elligo to analyze the women's health populations within the Elligo community to help reach timely enrollment goals.

According to the Centers for Disease Control and Prevention:

- HPV is the most common sexually transmitted infection in the U.S.
- 79 million Americans, mostly in their late teens and early 20s, are infected with HPV
- HPV 16 causes approximately 50% of cervical cancers worldwide
- The two most common cervical cancers are both caused by HPV


The Solution

Leveraging the IntElligo Research Stack™ platform, Elligo's data science specialists quickly went to work analyzing patient data. By accessing electronic health records and lab results from the past six months, they swiftly identified HPV 16 patients within Elligo's women's health community.

Results

The Elligo community of women's health sites enrolled its first patient in the study less than two weeks after the sites received approval. The study fully enrolled all patients required in the first stage within the originally targeted enrollment period, putting the study back on track. Having reduced the screen failure rate by about two-thirds, Elligo contributed over 90% of those patients within three months.

Phase II of the study is planned for 2020 and the customer is interested in utilizing Elligo's network to enroll the entire study.



TO LEARN MORE, VISIT [ELLIGODIRECT.COM](https://elligodirect.com) >

About Elligo Health Research

Elligo Health Research, a healthcare-enabling research organization, uses electronic health records and the trusted patient and physician relationship to ensure all patients have access to clinical research as a care option. Powered by our *Goes Direct*® approach and novel IntElligo Research Stack™ clinical technology, our team connects the best healthcare experts with the best technologies and infrastructure. We engage physicians and patients who otherwise would not participate in clinical research and accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products. Learn more at elligodirect.com.